The current price of IONS is $40.15 — it has decreased by 0.67% since the previous close. Data as of Nov 4, 2026.
IONS is down 10.16% over the past week, down 7.79% over the past month and down 44.91% over the past year. The price is below its 200-day moving average of $66.43.
Analysts' average 12-month price target for IONS is $84.92, which implies 111.51% upside from the current price. Individual estimates range from $56.00 to $115.00.
Of the 25 analysts covering Ionis Pharmaceuticals, Inc., 9 rate it a strong buy, 12 rate it a buy and 4 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Ionis Pharmaceuticals, Inc. has a market capitalization of $6.67B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Ionis Pharmaceuticals, Inc. posted a loss of $0.69 per share against an estimate of -$1.09, beating expectations by 36.70%. Upcoming reports are listed in the earnings calendar.
Ionis Pharmaceuticals, Inc. reported revenue of $268M in its most recent quarter, which has decreased by 40.71% compared with the same quarter a year earlier. Analysts had expected $189.1M.
Ionis Pharmaceuticals, Inc. has not paid any dividends over the past year.
In the latest trading session IONS moved between $39.33 and $41.53, a range of 5.47% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Ionis Pharmaceuticals, Inc. shows a sell rating today. Technical ratings are indicators, not investment advice.
Over the past 52 weeks IONS has traded between $39.33 and $86.74. The current price is 53.71% below its 52-week high.
Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.